# Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）

> **NCT05512520** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 126 (estimated)

## Conditions studied

- Metastatic Esophageal Squamous Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Intensity-modulated radiotherapy concurrent with capecitabine

## Key facts

- **NCT ID:** NCT05512520
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-20
- **Primary completion:** 2024-08-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512520, "Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05512520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*